Phase 1a Clinical Trial of XRD-0394, a First-in-Class Dual Ataxia-Telangiectasia Mutated and DNA-Dependent Protein Kinase Inhibitor, in Combination With Palliative Radiation Therapy.
Chen CT, Gensheimer MF, Gilmer TM, Stanley J et al. • International journal of radiation oncology, biology, physics
(2026)
PMC
PMC Public Access (View-Only)
DOI:
10.1016/j.ijrobp.2026.08.069
PMC: PMC13734973